Insulet announced that as of January 1, 2019, Shacey Petrovic (pictured below) will succeed Patrick Sullivan as Insulet’s CEO. For the last two years, Petrovic has served as the company’s President and Chief Operating Officer. Below, FENIX provides thoughts on the CEO succession and impact to Insulet moving forward.
Insulet hosted its Q2 ’18 earnings call and provided updates on its Omnipod business including pipeline activities for the Omnipod Horizon hybrid closed-loop. Below are highlights from the call.
4 major press releases featuring new data presented at ADA ’18 were observed across diabetes drugs and devices. Below, FENIX has provided context and analysis of these announcements.
As a follow-up to our drug analysis of 14 press releases, FENIX has provided context and analysis for 7 device and app-related announcements.
In the second installment of our post-AACE 2018 promotional material coverage (see first installment on diabetes drugs), FENIX has conducted an analysis of diabetes device promotional materials covering Dexcom G6, Abbott Freestyle Libre, Medtronic 670G, Insulet Omnipod, and Tandem t:slim X2.
Insulet has announced FDA 510(k) clearance of its next generation handheld personal diabetes manager (PDM) called “Omnipod DASH.” Below, FENIX provides insight into the DASH system including Insulet’s decision to give DASH away at no cost.
During Day 2 of JPM, presentations ranged across both diabetes drug (Sanofi, Lilly, Lexicon, and Mylan) and device manufacturers (Dexcom, Insulet, and Roche), although Mylan and Roche did not discuss their diabetes portfolios. Below, find key takeaways from JPM followed by more in-depth coverage.
Insulet hosted its Q4 ’17 earnings call and provided commercial and R&D business updates. Below are highlights from the call.